LifeStance Health Group, Inc. (LFST)
NASDAQ: LFST · Real-Time Price · USD
5.15
+0.07 (1.38%)
Jun 27, 2025, 4:00 PM - Market closed
LifeStance Health Group Stock Forecast
Stock Price Forecast
The 5 analysts that cover LifeStance Health Group stock have a consensus rating of "Strong Buy" and an average price target of $8.5, which forecasts a 65.05% increase in the stock price over the next year. The lowest target is $7 and the highest is $10.
Price Target: $8.5 (+65.05%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 27, 2025.
Analyst Ratings
The average analyst rating for LifeStance Health Group stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Buy | 1 | 1 | 1 | 2 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 6 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Hold → Strong Buy Upgrades $8.5 | Hold → Strong Buy | Upgrades | $8.5 | +65.05% | May 27, 2025 |
| Keybanc | Keybanc | Buy Initiates $9 | Buy | Initiates | $9 | +74.76% | Apr 8, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +55.34% | Apr 3, 2025 |
| Goldman Sachs | Goldman Sachs | Hold → Strong Buy Upgrades $10 | Hold → Strong Buy | Upgrades | $10 | +94.17% | Dec 16, 2024 |
| Barclays | Barclays | Sell Maintains $6 → $7 | Sell | Maintains | $6 → $7 | +35.92% | Nov 11, 2024 |
Financial Forecast
Revenue This Year
1.44B
from 1.25B
Increased by 15.27%
Revenue Next Year
1.64B
from 1.44B
Increased by 13.94%
EPS This Year
-0.05
from -0.15
EPS Next Year
0.03
from -0.05
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 1.5B | 1.7B | 2.0B |
| Avg | 1.4B | 1.6B | 1.9B |
| Low | 1.4B | 1.5B | 1.8B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 19.2% | 19.3% | 20.8% |
| Avg | 15.3% | 13.9% | 14.5% |
| Low | 9.7% | 7.0% | 8.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.01 | 0.14 | 0.26 |
| Avg | -0.05 | 0.03 | 0.18 |
| Low | -0.08 | -0.07 | 0.08 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | 662.5% |
| Avg | - | - | 433.3% |
| Low | - | - | 127.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.